Keros Therapeutics Shares Down

Keros halts blood pressure treatment trial on safety issues
Keros Therapeutics said on Wednesday it would voluntarily halt testing of an experimental blood pressure treatment due to safety concerns during a mid-stage trial, causing its shares to hit a record low.
Keros Therapeutics Shares Down After Halting Pulmonary Hypertension Treatment Trials
Shares in Keros Therapeutics fell sharply Wednesday morning after it said it halted trials of its treatment for pulmonary hypertension after finding adverse health effects in patients trialing the drug. Shares fell 16% to $10.54.
Keros Therapeutics stock falls after trial halt
Investing.com -- Shares of Keros Therapeutics (NASDAQ:KROS) tumbled 17% after the company announced a voluntary halt on all dosing in the TROPOS trial, which is evaluating cibotercept (KER-012) in patients with pulmonary arterial hypertension (PAH). The decision came as a result of new safety concerns related to pericardial effusion adverse events.
Keros Therapeutics Halts All Dosing In Phase 2 TROPOS Trial For PAH Due To Safety Concerns
Providing additional update on the Phase 2 TROPOS trial on Wednesday, biopharmaceutical company Keros Therapeutics, Inc. (KROS)
Keros Therapeutics Halts Pulmonary Hypertension Treatment Trials Due to Adverse Effects
Keros Therapeutics has halted the dosing of its treatment for pulmonary hypertension due to adverse health effects discovered during trials. The clinical-stage biopharmaceutical company said Wednesday that it has voluntarily halted all dosing in the phase 2 Tropos trial for the drug cibotercept, which aims to treat pulmonary arterial hypertension.
Hosted on MSN19h
Keros Therapeutics Stock Heads For Record Low After Dosing Halt In Pulmonary Disease Trial, Retail Buzz Spikes
Shares of Keros Therapeutics (KROS) plunged nearly 20% in premarket trading on Wednesday, poised to hit an all-time low after ...
FierceBiotech22h
Keros, after halting 2 cohorts over fluid buildups around heart, pulls plug on hypertension trial
A month after halting dosing in two of the three treatment arms of a phase 2 trial of its pulmonary arterial hypertension ...
Keros Therapeutics: Buy Rating Affirmed Despite Setbacks, Driven by Strong Pipeline and Strategic Partnerships
Analyst Jason Zemansky of Bank of America Securities reiterated a Buy rating on Keros Therapeutics (KROS – Research Report), reducing the price ...
pharmaphorum21h
Keros pulls study of Winrevair rival after safety signal
The action affects the TROPOS trial of cibotacept (KER-012), an activin signalling inhibitor that works in a similar way to ...
BioSpace19h
New Safety Signals Force Keros to Fully Terminate Mid-Stage PAH Study
Taken together with Keros’ recent pivot away from obesity, the termination of its pulmonary arterial hypertension study could ...
Keros Therapeutics price target lowered to $32 from $33 at BofA
BofA analyst Jason Zemansky lowered the firm’s price target on Keros Therapeutics (KROS) to $32 from $33 and keeps a Buy rating on the shares.
Keros Therapeutics, Inc. (NASDAQ:KROS) Receives $75.00 Consensus PT from Analysts
Shares of Keros Therapeutics, Inc. (NASDAQ:KROS – Get Free Report) have been assigned a consensus recommendation of “Moderate ...